Zydus Lifesciences Limited reported earnings results for the second quarter and six months ended September 30, 2024. For the second quarter, the company reported revenue was INR 53,052 million compared to INR 44,228 million a year ago. Net income was INR 9,112 million compared to INR 8,007 million a year ago. Basic earnings per share from continuing operations was INR 9.05 compared to INR 7.92 a year ago. Diluted earnings per share from continuing operations was INR 9.05 compared to INR 7.92 a year ago. Basic earnings per share was INR 9.06 compared to INR 7.91 a year ago. Diluted earnings per share was INR 9.06 compared to INR 7.91 a year ago.
For the six months, revenue was INR 115,759 million compared to INR 95,984 million a year ago. Net income was INR 23,311 million compared to INR 18,876 million a year ago. Basic earnings per share from continuing operations was INR 23.16 compared to INR 18.67 a year ago. Diluted earnings per share from continuing operations was INR 23.16 compared to INR 18.67 a year ago. Basic earnings per share was INR 23.17 compared to INR 18.65 a year ago. Diluted earnings per share was INR 23.17 compared to INR 18.65 a year ago.
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
